DCMA Policy

Coeptis Therapeutics Holdings, Inc. (“Company,” “we,” “us,” or “our”) respects the intellectual property rights of others and expects users of our website (the “Website”) to do the same. In accordance with the Digital Millennium Copyright Act (“DMCA”), we have adopted the following policy for addressing claims of copyright infringement.

We will:

1. Remove or disable access to material that we believe in good faith infringes copyright; and
2. Terminate access for users who are repeat infringers, where appropriate.

A. Reporting Copyright Infringement

If you believe that any content on or accessible through the Website infringes your copyright, you may submit a notification to our designated agent with the following information:

1. A physical or electronic signature of a person authorized to act on behalf of the copyright owner;
2. Identification of the copyrighted work(s) claimed to have been infringed;
3. Identification of the material claimed to be infringing, including sufficient detail to allow us to locate it on the Website;
4. Your contact information, including name, address, telephone number, and, if available, email address;
5. A statement that you have a good faith belief that the use of the material is not authorized by the copyright owner, its agent, or the law; and
6. A statement, under penalty of perjury, that the information provided is accurate and that you are authorized to act on behalf of the copyright owner.

B. Our Response to Proper Notices

Upon receipt of a valid DMCA notice, we will:

1. Remove or disable access to the allegedly infringing material;
2. Notify the user who posted the material; and
3. Take appropriate action against repeat infringers, which may include termination of access to the Website.

C. Counter-Notification Procedure

If you believe that material you posted was removed or disabled by mistake or misidentification, you may submit a counter-notification to our designated agent containing the following:

1. Your physical or electronic signature;
2. Identification of the material that was removed or disabled and the location where it appeared before removal;
3. A statement, under penalty of perjury, that you have a good faith belief the material was removed or disabled as a result of mistake or misidentification; and
4. Your name, address, telephone number, and email address, along with a statement that:
   • You consent to the jurisdiction of the federal court in your district of residence (or, if outside the United States, any judicial district in which the Company is located); and
   • You will accept service of process from the person who submitted the original infringement notice.

D. Restoration of Content

If we receive a valid counter-notification, we may send a copy to the original complaining party. Unless that party files a legal action seeking a court order, we may restore the removed material within 10–14 business days after receiving the counter-notice, at our discretion.

E. Designated Agent

DMCA notices and counter-notices should be sent to:

Coeptis Therapeutics Holdings, Inc.
Attn: DMCA Designated Agent
105 Bradford Road, Suite 420
Wexford, PA 15090
Email: info@coeptistx.com

F. Important Notice

Failure to comply with all of the requirements outlined above may render your DMCA notice or counter-notification invalid.